Vandetanib
Chemical compound / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Vandetanib?
Summarize this article for a 10 year old
SHOW ALL QUESTIONS
Vandetanib, sold under the brand name Caprelsa, is an anti-cancer medication that is used for the treatment of certain tumours of the thyroid gland. It acts as a kinase inhibitor of a number of cell receptors, mainly the vascular endothelial growth factor receptor (VEGFR), the epidermal growth factor receptor (EGFR), and the RET-tyrosine kinase.[3][4] The drug was developed by AstraZeneca[2] who later sold the rights to Sanofi in 2015.[5][6]
Quick Facts Clinical data, Trade names ...
Clinical data | |
---|---|
Trade names | Caprelsa |
Other names | ZD6474 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a611037 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Protein binding | 90–96% |
Metabolism | CYP3A4, FMO1, FMO3 |
Elimination half-life | 19 days (mean)[2] |
Excretion | 44% faeces, 25% urine |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank |
|
ChemSpider |
|
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
PDB ligand | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.195.611 |
Chemical and physical data | |
Formula | C22H24BrFN4O2 |
Molar mass | 475.362 g·mol−1 |
3D model (JSmol) | |
| |
| |
NY (what is this?) (verify) |
Close